Janus Kinase (JAK) Inhibitors Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Ph

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Janus Kinase (JAK) Inhibitors pipeline constitutes key companies continuously working towards developing Janus Kinase (JAK) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Janus Kinase (JAK) Inhibitors Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Janus Kinase (JAK) Inhibitors Market.

The Janus Kinase (JAK) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Janus Kinase (JAK) Inhibitors Pipeline Report: https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Janus Kinase (JAK) Inhibitors treatment therapies with a considerable amount of success over the years.
• Janus Kinase (JAK) Inhibitors companies working in the treatment market are Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others, are developing therapies for the Janus Kinase (JAK) Inhibitors treatment
• Emerging Janus Kinase (JAK) Inhibitors therapies in the different phases of clinical trials are- SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others are expected to have a significant impact on the Janus Kinase (JAK) Inhibitors market in the coming years.
• In December 2022, Incyte Corporation has commenced a Phase III clinical trial, employing a double-blind, randomized, and placebo-controlled design, to assess the efficacy and safety of povorcitinib (INCB054707) in individuals with moderate to severe hidradenitis suppurativa. The study spans a 12-week placebo-controlled phase, followed by a 42-week extension period. The anticipated completion date for the trial is March 2025, with an estimated enrollment of 600 participants.
• In October 2022, AbbVie revealed that the U.S. Food and Drug Administration (FDA) has granted approval for upadacitinib (marketed as Rinvoq), a Janus kinase (JAK) inhibitor. The approval is specifically for adults diagnosed with non-radiographic axial spondyloarthritis (nr-axSpA) exhibiting objective signs of inflammation and experiencing an inadequate response to or intolerance of one or more tumor necrosis factor (TNF) inhibitors.
• In October 2022, Incyte reported that findings from the crucial Phase III TRuE-V clinical trial program, which assessed the efficacy of ruxolitinib cream (marketed as OpzeluraTM) at a 1.5% concentration in patients aged 12 and above diagnosed with nonsegmental vitiligo, have been published in "The New England Journal of Medicine (NEJM)."
• In September 2022, Bristol Myers Squibb has unveiled new two-year findings from the POETYK PSO long-term extension (LTE) trial, revealing that continuous treatment with Sotyktu™ (deucravacitinib) maintains clinical efficacy in adult patients with moderate-to-severe plaque psoriasis. This assessment focused on patients who transitioned from the pivotal POETYK PSO-1 trial into the LTE trial. After 112 weeks of Sotyktu treatment, response rates, as per modified non-responder imputation (mNRI), were 82.4% for Psoriasis Area and Severity Index (PASI) 75, 55.2% for PASI 90, and 66.5% for static Physician's Global Assessment (sPGA) 0/1.
• In July 2022, AbbVie has reported the submission of applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for a new indication for upadacitinib (marketed as RINVOQ®, with an induction dose of 45 mg and maintenance doses of 15 mg and 30 mg). This new indication aims to secure approval for the treatment of adult patients dealing with moderately to severely active Crohn's disease.

Janus Kinase (JAK) Inhibitors Overview
Janus Kinase (JAK) inhibitors are a class of medications that target and block the activity of Janus Kinases, a family of enzymes involved in cell signaling. JAKs play a crucial role in transmitting signals from various cytokines and growth factors to influence cellular processes such as immune response, inflammation, and hematopoiesis (formation of blood cells).

Get a Free Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Janus Kinase (JAK) Inhibitors Drugs Under Different Phases of Clinical Development Include:
• SDC-1801: Sareum
• CS-32582: Chipscreen Biosciences
• ATI-2138: Aclaris Therapeutics
• PF-07295324: Pfizer
• EQ-121: EQRx
• CPL409116: Celon Pharma
• TD-0903: Theravance Biopharma
• Ivarmacitinib: Reistone Biopharma
• CTP-543: Concert Pharmaceuticals
• Povorcitinib: Incyte Corporation

Janus Kinase (JAK) Inhibitors Pipeline Therapeutics Assessment
• Janus Kinase (JAK) Inhibitors Assessment by Product Type
• Janus Kinase (JAK) Inhibitors By Stage and Product Type
• Janus Kinase (JAK) Inhibitors Assessment by Route of Administration
• Janus Kinase (JAK) Inhibitors By Stage and Route of Administration
• Janus Kinase (JAK) Inhibitors Assessment by Molecule Type
• Janus Kinase (JAK) Inhibitors by Stage and Molecule Type
DelveInsight's Janus Kinase (JAK) Inhibitors Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Janus Kinase (JAK) Inhibitors product details are provided in the report. Download the Janus Kinase (JAK) Inhibitors pipeline report to learn more about the emerging Janus Kinase (JAK) Inhibitors therapies at:
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Janus Kinase (JAK) Inhibitors Therapeutics Market include:
Key companies developing therapies for Janus Kinase (JAK) Inhibitors are - Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., Novartis Pharmaceuticals, Eli Lilly and Company, Kartos Therapeutics, Telios Pharma, Kiniksa Pharmaceuticals, Celgene, GlaxoSmithKline, Abivax S.A., Dizal Pharmaceuticals, Constellation Pharmaceuticals, MaaT Pharma, Galvani Bioelectronics, CTI BioPharma, Crescendo Bioscience, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Astellas Pharma, Imago BioSciences, and others.

Janus Kinase (JAK) Inhibitors Pipeline Analysis:
The Janus Kinase (JAK) Inhibitors pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Janus Kinase (JAK) Inhibitors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Janus Kinase (JAK) Inhibitors Treatment.
• Janus Kinase (JAK) Inhibitors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Janus Kinase (JAK) Inhibitors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Janus Kinase (JAK) Inhibitors market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Janus Kinase (JAK) Inhibitors drugs and therapies-
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Janus Kinase (JAK) Inhibitors Pipeline Market Drivers
• Rising prevalence of chronic and autoimmune disease, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Janus Kinase (JAK) Inhibitors Market.

Janus Kinase (JAK) Inhibitors Pipeline Market Barriers
• However, high cost of treatment, regulatory challenges in the launch of JAK inhibitors and other factors are creating obstacles in the Janus Kinase (JAK) Inhibitors Market growth.

Scope of Janus Kinase (JAK) Inhibitors Pipeline Drug Insight
• Coverage: Global
• Key Janus Kinase (JAK) Inhibitors Companies: Sareum, Chipscreen Biosciences, Aclaris Therapeutics, Pfizer, EQRx, Celon Pharma, Theravance Biopharma, Reistone Biopharma, Concert Pharmaceuticals, Incyte Corporation, and others
• Key Janus Kinase (JAK) Inhibitors Therapies: SDC-1801, CS-32582, ATI-2138, PF-07295324, EQ-121, CPL409116, TD-0903, Ivarmacitinib, CTP-543, Povorcitinib, and others
• Janus Kinase (JAK) Inhibitors Therapeutic Assessment: Janus Kinase (JAK) Inhibitors current marketed and Janus Kinase (JAK) Inhibitors emerging therapies
• Janus Kinase (JAK) Inhibitors Market Dynamics: Janus Kinase (JAK) Inhibitors market drivers and Janus Kinase (JAK) Inhibitors market barriers

Request for Sample PDF Report for Janus Kinase (JAK) Inhibitors Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Janus Kinase (JAK) Inhibitors Report Introduction
2. Janus Kinase (JAK) Inhibitors Executive Summary
3. Janus Kinase (JAK) Inhibitors Overview
4. Janus Kinase (JAK) Inhibitors- Analytical Perspective In-depth Commercial Assessment
5. Janus Kinase (JAK) Inhibitors Pipeline Therapeutics
6. Janus Kinase (JAK) Inhibitors Late Stage Products (Phase II/III)
7. Janus Kinase (JAK) Inhibitors Mid Stage Products (Phase II)
8. Janus Kinase (JAK) Inhibitors Early Stage Products (Phase I)
9. Janus Kinase (JAK) Inhibitors Preclinical Stage Products
10. Janus Kinase (JAK) Inhibitors Therapeutics Assessment
11. Janus Kinase (JAK) Inhibitors Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Janus Kinase (JAK) Inhibitors Key Companies
14. Janus Kinase (JAK) Inhibitors Key Products
15. Janus Kinase (JAK) Inhibitors Unmet Needs
16 . Janus Kinase (JAK) Inhibitors Market Drivers and Barriers
17. Janus Kinase (JAK) Inhibitors Future Perspectives and Conclusion
18. Janus Kinase (JAK) Inhibitors Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Janus Kinase (JAK) Inhibitors Market https://www.delveinsight.com/report-store/janus-kinase-jak-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Janus Kinase (JAK) Inhibitors Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom).
Latest Reports:
B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.